By Anthony O. Goriainoff

AstraZeneca PLC said Friday that its cancer drug Lynparza showed an overall survival in men with metastatic castration-resistant prostate cancer during a Phase 3 PROfound trial.

The pharmaceutical giant said the drug showed significant clinical benefit across key endpoints in PROfound testing, including overall survival for male patients with breast cancer genes or ATM mutations, and that the drug's safety and tolerability profile was generally compatible with previous trials.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

April 24, 2020 02:35 ET (06:35 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more AstraZeneca Charts.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more AstraZeneca Charts.